We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Prostate Cancer Detected in Blood Using Flow Cytometry

By LabMedica International staff writers
Posted on 22 Feb 2016
Current methods of detecting prostate cancer, such as the prostate-specific antigen (PSA) test and biopsies, have limitations. More...
PSA tests are based on measuring a specific protein released by the prostate gland, but do not provide a definitive diagnosis.

A physical exam and biopsy are needed if PSA levels are elevated; however, even the painful biopsy procedure has a 15% error rate. During biopsies, a painful and invasive procedure, 12 needles are inserted into the rectum, with the hope of extracting material from an area with a tumor.

A team of scientists at the Western University's Schulich School of Medicine and Dentistry (London, ON, Canada) and at Lawson Health Research Institute (London, ON, Canada) have repurposed a machine once used to detect airborne pathogens in the second Gulf War. The machine is now used for fluid biopsies, a noninvasive way to detect prostate microparticles in the blood in a matter of minutes. Microparticles are essentially refuse released by prostate cells that circulate throughout the bloodstream.

The machine was used in the Gulf War, and more commonly to test water purity and the machine uses flow cytometry (Apogee Flow Systems; Hemel Hempstead, UK) to detect microparticles. Flow cytometry measures the specific characteristics of a fluid, such as blood, as it passes through a laser. Most men, who are more than 40 years old, regardless of their health, have detectable levels of prostate microparticles in their bloodstream. The scientists have conducted the first clinical cancer project to correlate the number of microparticles in the blood to the risk of having prostate cancer in that the more microparticles, the higher the risk.

The study provides a more accurate and less invasive testing method for patients suspected of having prostate cancer, and helps to identify patients who are at a higher risk of dying from prostate cancer. Hon Leong, PhD, an assistant professor and team leader, said, “Our findings point to a new direction in how we can better identify patients who actually have prostate cancer. With this test, we can improve the clinical outcomes for patients, reducing costs for unnecessary procedures and reducing errors in diagnosis.”

Related Links:

Western University's Schulich School of Medicine and Dentistry
Lawson Health Research Institute
Apogee Flow Systems



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.